Invention Reference Number
Cancers driven by intracellular oncogenic targets remain difficult to treat due to therapy resistance and the challenges of effectively targeting proteins inside cells. This technology introduces a targeted approach that delivers therapeutic or imaging radioisotope payloads directly to mutant protein expressing cancer cells. By combining selective molecular recognition with localized delivery, it aims to improve treatment effectiveness while limiting impact on healthy tissue. The platform’s adaptable design also enables application across multiple cancer types, supporting the development of more durable treatment and diagnostic options.
Description
This technology is based on a modular small-molecule construct designed to selectively bind to cancer cells expressing a specific oncogenic protein mutation and deliver a radioactive payload. The construct integrates a targeting ligand, a linker system, and a payload-binding component into a single entity. Upon binding the target, the construct forms a stable attachment within the cell, enabling localized delivery of a radionuclide. The platform supports incorporation of different payload types, allowing use in both treatment and diagnostic applications. The modular architecture allows substitution of targeting elements, enabling expansion to other cancer signatures. This approach is designed to address resistance mechanisms through a targeted and sustained irradiation of cancer cells.
Benefits
- Targeted delivery to mutation-expressing cells
- Enhanced therapeutic effect compared to non-radioactive approaches
- Reduced exposure to non-target tissues
- Adaptable platform for multiple targets and payloads applications and industries
Applications and Industries
- Oncology drug development
- Molecular imaging and diagnostics
- Precision medicine platforms
- Pharmaceutical and biotechnology industries
Contact
To learn more about this technology, email partnerships@ornl.gov or call 865-574-1051.
